ProDERM study results of Octagam® 10% treatment in patients with dermatomyositis published in the New England Journal of Medicine (IMAGE)

Yankee Public Relations

ProDERM study results of Octagam® 10% treatment in patients with dermatomyositis published in the New England Journal of Medicine

Caption

Octapharma announced today the results from the ProDERM study on the efficacy and safety of Octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in the New England Journal of Medicine (Aggarwal R et al. “Trial of Intravenous Immune Globulin in Dermatomyositis”)

Credit

Octapharma USA

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.